Profile data is unavailable for this security.
About the company
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on advancing novel therapeutics targeting retinal degenerative eye disease, such as Geographic Atrophy (GA), age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. Its lead product candidate, Tinlarebant, is an oral daily treatment for STGD1 and GA patients. In STGD1, it is developing Tinlarebant as a once-a-day tablet treatment to target Retinol binding protein 4 (RBP4) by disrupting vitamin A (retinol) binding to RBP4, which leads to reduced delivery of retinol to the eye and reduced accumulation of toxic vitamin A by-products. Its product candidate also includes LBS-009, an anti-RBP4 oral therapy targeting liver disease, including NAFLD, NASH, and T2D.
- Revenue in USD (TTM)0.00
- Net income in USD-49.38m
- Incorporated2018
- Employees25.00
- LocationBelite Bio Inc12750 High Bluff Drive Suite 475SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 246-6240
- Websitehttps://belitebio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scholar Rock Holding Corp | 0.00 | -353.43m | 4.69bn | 196.00 | -- | 18.61 | -- | -- | -3.15 | -3.15 | 0.00 | 2.47 | 0.00 | -- | -- | 0.00 | -119.63 | -45.06 | -144.40 | -51.62 | -- | -- | -- | -1,134.62 | -- | -- | 0.2891 | -- | -- | -- | -48.56 | -- | -49.93 | -- |
| Celcuity Inc | 0.00 | -162.72m | 4.84bn | 87.00 | -- | 38.67 | -- | -- | -3.67 | -3.67 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -43.45 | -42.61 | -47.58 | -45.75 | -- | -- | -- | -- | -- | -48.30 | 0.7325 | -- | -- | -- | -75.26 | -- | -8.05 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -210.69m | 4.84bn | 218.00 | -- | -- | -- | -- | -3.65 | -3.65 | 0.00 | -- | 0.00 | -- | -- | 0.00 | -23.87 | -- | -25.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -36.72 | -- | -- | -- |
| Protagonist Therapeutics Inc | 209.22m | 45.91m | 5.09bn | 128.00 | 129.07 | 7.88 | 107.59 | 24.35 | 0.6313 | 0.6313 | 3.26 | 10.34 | 0.3205 | -- | 52.34 | 1,660,452.00 | 7.03 | -7.11 | 7.55 | -7.93 | -- | -- | 21.94 | -21.29 | -- | -- | 0.00 | -- | 624.06 | 351.71 | 448.54 | -- | 6.98 | -- |
| Immunovant Inc | 0.00 | -464.20m | 5.24bn | 362.00 | -- | 5.31 | -- | -- | -2.68 | -2.68 | 0.00 | 4.85 | 0.00 | -- | -- | 0.00 | -63.01 | -47.00 | -69.35 | -51.13 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -59.58 | -- | 89.57 | -- |
| Alkermes Plc | 1.52bn | 338.06m | 5.48bn | 1.80k | 16.43 | 3.16 | 14.87 | 3.60 | 2.02 | 2.02 | 9.06 | 10.50 | 0.6784 | 1.11 | 4.20 | 845,187.80 | 15.08 | 6.99 | 19.01 | 9.14 | 86.04 | 83.31 | 22.22 | 10.68 | 3.27 | -- | 0.00 | 0.00 | -6.36 | 5.87 | -28.32 | -- | -18.11 | -- |
| Immunitybio Inc | 82.56m | -348.62m | 5.86bn | 673.00 | -- | -- | -- | 70.93 | -0.4079 | -0.4079 | 0.0965 | -0.5323 | 0.1869 | 0.0857 | 4.56 | 121,404.40 | -78.93 | -109.27 | -91.33 | -251.12 | 90.40 | -- | -422.38 | -11,599.51 | 5.65 | -2.20 | 2.77 | -- | 2,270.58 | 46.27 | 29.09 | -- | 9.95 | -- |
| Cogent Biosciences Inc | 0.00 | -214.77m | 6.40bn | 205.00 | -- | 26.26 | -- | -- | -1.77 | -1.77 | 0.00 | 2.16 | 0.00 | -- | -- | 0.00 | -72.69 | -57.20 | -84.75 | -63.62 | -- | -- | -- | -9,345.59 | -- | -- | 0.1276 | -- | -- | -- | -30.01 | -- | 76.98 | -- |
| Kymera Therapeutics Inc | 43.73m | -295.12m | 6.57bn | 225.00 | -- | 6.24 | -- | 150.23 | -3.59 | -3.59 | 0.5332 | 13.19 | 0.0409 | -- | 66.41 | 232,627.70 | -27.62 | -23.82 | -29.53 | -27.88 | -- | -- | -674.81 | -240.35 | -- | -- | 0.0039 | -- | -40.11 | 74.20 | -52.32 | -- | 89.02 | -- |
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.57bn | 25.00 | -- | 38.25 | -- | -- | -1.55 | -1.55 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| ICON PLC | 8.10bn | 599.48m | 7.10bn | 39.80k | 12.57 | 0.7608 | 7.19 | 0.8764 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Vaxcyte Inc | 0.00 | -657.20m | 7.63bn | 414.00 | -- | 2.43 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.79bn | 218.00 | -- | 8.62 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 7.94bn | 18.60k | -- | 2.33 | 22.85 | 1.97 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 8.10bn | 498.00 | -- | -- | -- | 92.89 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
Data as of Feb 13 2026. Currency figures normalised to Belite Bio Inc's reporting currency: US Dollar USD
13.18%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Darwin Global Management Ltd.as of 03 Dec 2025 | 2.62m | 6.98% |
| RA Capital Management LPas of 30 Sep 2025 | 875.00k | 2.33% |
| Vestal Point Capital LPas of 30 Sep 2025 | 312.50k | 0.83% |
| RTW Investments LPas of 30 Sep 2025 | 312.50k | 0.83% |
| Soleus Capital Management LP (Investment Management)as of 30 Sep 2025 | 210.00k | 0.56% |
| Eventide Asset Management LLCas of 30 Sep 2025 | 195.31k | 0.52% |
| Marshall Wace LLPas of 30 Sep 2025 | 187.50k | 0.50% |
| UBS Securities LLCas of 31 Dec 2025 | 94.30k | 0.25% |
| Fubon Asset Management Co., Ltd.as of 31 Dec 2025 | 79.97k | 0.21% |
| Western Standard LLCas of 31 Dec 2025 | 60.03k | 0.16% |
More ▼
Data from 30 Sep 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
